<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Terrell Lucas | Activity</title>
	<link>https://www.catswannabecats.com/members/bladesun2/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/bladesun2/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Terrell Lucas.</description>
	<lastBuildDate>Mon, 06 Jul 2026 08:03:58 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">31c891945b1c5d641251eaed1cd40774</guid>
				<title>Terrell Lucas posted an update: s exhibited polyfunctional effector responses to two novel [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/22079/</link>
				<pubDate>Sat, 07 Jun 2025 08:02:47 -0400</pubDate>

									<content:encoded><![CDATA[<p>s exhibited polyfunctional effector responses to two novel NC-derived peptides identified as HLA-binders. These studies provide a proof of concept that our immunoinformatics analysis pipeline identifies novel immunogens which can elicit polyfunctional SARS-CoV-2-specific T-cell responses.Idiopathic pulmonary fibrosis (IPF) is characterized by&hellip;<span class="activity-read-more" id="activity-read-more-22079"><a href="https://www.catswannabecats.com/activity/p/22079/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">cc2c9761e9a64facef4167e882eaf36d</guid>
				<title>Terrell Lucas posted an update: in Asians.



 Allogeneic hematopoietic stem cell [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/2684/</link>
				<pubDate>Sat, 31 May 2025 08:56:14 -0400</pubDate>

									<content:encoded><![CDATA[<p>in Asians.</p>
<p> Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the curative therapy for acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), but advanced age with multiple comorbidities limits the eligibility for allo-HSCT. We conducted a retrospective study to investigate the comorbidities assessments&hellip;<span class="activity-read-more" id="activity-read-more-2684"><a href="https://www.catswannabecats.com/activity/p/2684/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">3c499b2624b89a5aa1bdd8b9e6ad1ded</guid>
				<title>Terrell Lucas posted an update: in Asians.



 Allogeneic hematopoietic stem cell [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/2625/</link>
				<pubDate>Sat, 31 May 2025 08:44:57 -0400</pubDate>

									<content:encoded><![CDATA[<p>in Asians.</p>
<p> Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the curative therapy for acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), but advanced age with multiple comorbidities limits the eligibility for allo-HSCT. We conducted a retrospective study to investigate the comorbidities assessments&hellip;<span class="activity-read-more" id="activity-read-more-2625"><a href="https://www.catswannabecats.com/activity/p/2625/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f1202b166dd37b1a44bc137d0c2ac5f3</guid>
				<title>Terrell Lucas became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/2427/</link>
				<pubDate>Sat, 31 May 2025 08:16:47 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>